COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The START Study Observes Afatinib as First-line Treatment and Sequential Therapy in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Nonsmall Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04206787
Recruitment Status : Recruiting
First Posted : December 20, 2019
Last Update Posted : January 12, 2021
Information provided by (Responsible Party):
Boehringer Ingelheim

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 15, 2023
Estimated Study Completion Date : October 15, 2025